In an unusual move, the FDA has approved the diabetes drug Symlin on condition of a series of heavy advertising restrictions. The agreement between the agency and manufacturer Amylin calls for a ban ...
XP-3924 showed promising glucose control when compared to both Humulin® R and co-administered injections of Humulin® R and Symlin® XP-3924 was observed to be safe and well tolerated in this study ...
In the rollercoaster world of biotech fortunes, San Diego's Amylin Pharmaceuticals has taken its fair share of bumps. The firm, founded in 1987, survived the loss of a big pharmaceutical partner, a ...
Amylin Pharmaceuticals is down 84 cents, or 5 percent, to $15.92, after the San Diego firm said that it has withdrawn the marketing application for Symlin, its diabetes drug candidate, in Europe. The ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In patients with type 1 diabetes, the use of Symlin ...
WASHINGTON, June 25 (UPI) -- Amylin presented data at the American Diabetes Association meeting suggesting Symlin improves control of diabetes when used in combination with another drug, leading some ...
LOS ANGELES (MarketWatch) -- Shares of Amylin Pharmaceuticals jumped 6 percent Thursday after the Food and Drug Administration approved Symlin, the company's diabetes treatment. Shares of Amylin AMLN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results